EU Commission Misses Chance To Offer Guidance On Patent Settlements
This article was originally published in The Pink Sheet Daily
Executive Summary
The European Commission has published its fourth report in monitoring patent settlements, but again has failed to offer pharma companies guidance on how to avoid potential competition abuses.
You may also be interested in...
EU Commission's Attack On Pharma Pay-For-Delay “Is Misguided”
The EU Commission's assumption that pharma pay-for-delay settlements are anti-competitive is by no means water-tight, a senior IP and competition lawyer suggests.
Servier’s EU Nightmare Continues As Commission Moves To Shut Down Disputed IP Practices
The European Commission’s allegations against Servier for alleged patent abuses could help to clarify the law in this area for original product manufacturers in the long term.
Quelle Surprise! EU Investigators Raid Pharma Firms
Government officials investigate possible obstacles to competition in the drug industry, expect a preliminary report this fall.